Literature DB >> 15905327

Role of IL-6 in systemic angiogenesis of the lung.

Jessica Y McClintock1, Elizabeth M Wagner.   

Abstract

The multifunctional cytokine interleukin (IL)-6 has been shown to modulate inflammation and angiogenesis. In a mouse model of lung angiogenesis induced by chronic left pulmonary artery ligation (LPAL), we previously showed increased expression of IL-6 mRNA in lung homogenates 4 h after the onset of pulmonary ischemia. To determine whether IL-6 influences both new vessel growth and inflammatory cell influx, we studied wild-type (WT) and IL-6-deficient C57Bl/6J (KO) mice after LPAL (4 h and 1, 7, 14 days). We measured IL-6 protein of the lung by ELISA, the lavage cell profile of the left lung, and new systemic vessel growth with radiolabeled microspheres (14 days after LPAL) in WT and KO mice. We confirmed a 2.4-fold increase in IL-6 protein in the left lung of WT mice compared with right lung 4 h after LPAL. A significant increase in lavaged neutrophils (7.5% of total cells) was observed only in WT mice 4 h after LPAL. New vessel growth was significantly attenuated in KO relative to WT (0.7 vs. 1.9% cardiac output). In an additional series, treatment of WT mice with anti-neutrophil antibody demonstrated a reduction in lavaged neutrophils 4 h after LPAL; however, IL-6 protein remained elevated and neovascularization to the left lung (2.3% cardiac output) was not altered. These results demonstrate that IL-6 plays an important modulatory role in lung angiogenesis, but the changes are not dependent on trapped neutrophils.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905327     DOI: 10.1152/japplphysiol.00006.2005

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  15 in total

1.  Progressive renal vascular proliferation and injury in obese Zucker rats.

Authors:  Radu Iliescu; Alejandro R Chade
Journal:  Microcirculation       Date:  2010-05       Impact factor: 2.628

2.  Cytokine production by the tumor from patients with breast cancer in different age groups.

Authors:  T A Kunts; E S Mikhaylova; I O Marinkin; N A Varaksin; A I Autenshlyus; V V Lyakhovich
Journal:  Dokl Biol Sci       Date:  2017-09-01

3.  Differential activity of pro-angiogenic CXC chemokines.

Authors:  Aigul Moldobaeva; Amy Baek; Lindsey Eldridge; Elizabeth M Wagner
Journal:  Microvasc Res       Date:  2010-02-06       Impact factor: 3.514

4.  Lung Angiogenesis Requires CD4(+) Forkhead Homeobox Protein-3(+) Regulatory T Cells.

Authors:  Franco R D'Alessio; Qiong Zhong; John Jenkins; Aigul Moldobaeva; Elizabeth M Wagner
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

5.  Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF-kappaB signaling pathway.

Authors:  Jelena Pistolic; Celine Cosseau; Yuexin Li; Jie Jessie Yu; Niall C J Filewod; Shaan Gellatly; Linda M Rehaume; Dawn M E Bowdish; Robert E W Hancock
Journal:  J Innate Immun       Date:  2008-11-06       Impact factor: 7.349

6.  Lung and vascular function during chronic severe pulmonary ischemia.

Authors:  Elizabeth M Wagner; John Jenkins; Maria Grazia Perino; Adlah Sukkar; Wayne Mitzner
Journal:  J Appl Physiol (1985)       Date:  2010-12-09

7.  INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma.

Authors:  Jinming Yang; Sara Kantrow; Jiqing Sai; Oriana E Hawkins; Mark Boothby; Gregory D Ayers; Eric D Young; Elizabeth G Demicco; Alexander J Lazar; Dina Lev; Ann Richmond
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

8.  Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.

Authors:  Paul D Upton; Rachel J Davies; Richard C Trembath; Nicholas W Morrell
Journal:  J Biol Chem       Date:  2009-04-14       Impact factor: 5.157

Review 9.  Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.

Authors:  George C Prendergast; William J Malachowski; Arpita Mondal; Peggy Scherle; Alexander J Muller
Journal:  Int Rev Cell Mol Biol       Date:  2017-09-21       Impact factor: 6.813

Review 10.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.